Prospective evaluation of Epstein-Barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy.

Patrizia Chiusolo, Paola Cattani, Nicola Piccirillo, Rosaria Santangelo, Simona Sica, Stefania Manzara, Silvia Bellesi, Teresa De Michele, Giuseppe Leone, Elisabetta Metafuni

Research output: Contribution to journalArticlepeer-review

20 Citations (Scopus)

Abstract

Epstein-Barr Virus (EBV) reactivation and EBV-related post-transplant lymphoproliferative disease (PTLD) have emerged as a severe complication after stem cell transplantation (SCT). We prospectively evaluated 104 consecutive patients receiving SCT either autologous or allogeneic. Fifty-two patients (50%) presented EBV DNA-emia and five of them developed PTLD proven or probable. PTLD rate was 9.6% among patients with EBV DNA-emia. One patient developed PTLD without EBV DNA-emia (0.96%). Overall PTLD incidence was 5.7%. No PTLD developed after autologous SCT. EBV DNA-emia was significantly more frequent after allogeneic than autologous SCT (60.7% vs 17.4%, p = 0.0002). At EBV reactivation, serum protein electrophoresis and immunofixation were assessed. Global incidence of γ-peak after allogeneic SCT with EBV reactivation was 65.3% (32/49 patients) and monoclonal gammopathy (MG) was identified in 23/28 evaluable patients (82%). All patients with PTLD developed γ-peak and in five of them MG was identified. MG is consistently associated with EBV DNA-emia and may help identification of progression to PTLD after allogeneic SCT.
Original languageEnglish
Pages (from-to)894-902
Number of pages9
JournalJournal of Clinical Immunology
Volume30
Publication statusPublished - 2010

Keywords

  • EBV
  • monoclonal gammopathy

Fingerprint

Dive into the research topics of 'Prospective evaluation of Epstein-Barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy.'. Together they form a unique fingerprint.

Cite this